Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company that develops psychedelic and related drugs to treat mental illnesses.
Gilgamesh Pharmaceuticals has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Gilgamesh Pharmaceuticals's investors include Alumni Ventures, Gaingels, Y Combinator, Pioneer Fund, Bossa Invest.
Gilgamesh Pharmaceuticals is headquartered in New York, United States.
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company that develops psychedelic and related drugs to treat mental illnesses.
Gilgamesh Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gilgamesh Pharmaceuticals — Funding & Investors." VCBacked, March 24, 2026, https://www.vcbacked.co/company/gilgamesh-pharmaceuticals. Accessed August 13, 2026.
VCBacked. (2026). Gilgamesh Pharmaceuticals — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/gilgamesh-pharmaceuticals
{{cite web |title=Gilgamesh Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/gilgamesh-pharmaceuticals |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated